CellGENTherapies
CellGENTherapies produces advanced gene-, cell- and tissue-therapeutic products (ATMPs) for early phase clinical trials according to good manufacturing principles (GMP).
We focus on the development and production of small batches of ATMPs (including personalized products) and prophylactic RNA vaccines for phase I studies helping UZ Gent, external clients and partners to move their research “from bench to bedside”.
News & Events
-
CellGENTherapies is partner in the EU co-funded ATMP XB project
CellGENTherapies is partner in the EU co-funded ATMP XB project, aiming to strengthen the Flemish–Dutch border region as a leading hub for ATMP research and development by providing reliable infrastructure, fostering innovation, building knowledge and creating strong cross-border collaboration. ATMPs (advanced therapy medicinal products) include cell and gene therapies that use living cells or genetically…
-
The new GMP facilities of Ghent University Hospital are entering the next phase.
In March this year, CellGENTherapies has announced their one full floor new GMP facility in the Nobel Building on Ghent University campus. This initiative is being funded by EFRO, FWO and the Ghent University Hospital. The team has worked hard to review the design plans of the cutting-edge cleanrooms with a focus on optimal processing…
CellGENTherapies is a member of
Vaxadvance is an initiative at Ghent University Hospital driven by four high level expertise centra who have strengthen their forces with the goal to accelerate breakthroughs in vaccine and therapeutic development.
- NanoMedicine Centre: nanoparticle-based formulation services
- the GMP unit CellGENTherapies: GMP production of ATMPs for early phase clinical trials
- the core ARTH Animal Facilities: lab animal-based preclinical research
- the Center for Vaccinology CEVAC: dedicated trial center Phase I – IV and Immuno-monitoring
With Vaxadvance, Ghent University Hospital continues playing a crucial role in driving the future of vaccine innovation.
Partners
Sponsors
